

INDEX

Note: Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

Clinical trials and studies are indexed under the acronym of the name; cross-references are provided from the full name.

- AASK (African American Study of Kidney Disease and Hypertension), 79, 153, 188-190, 200-201, 290t. See also *Black patients*.
- ABCD (Appropriate Blood Pressure Control in Diabetes) study, 78, 152-153, 153t, 290t
- ABPM. See *Ambulatory blood pressure monitoring (ABPM)*.
- Accupril (quinapril), 119t
- Accuretic, 113t, 250t
- ACE (angiotensin-converting enzyme) inhibitors, 117-154, 119t. See also *specific drugs*.
- action mechanisms, 117, 118, 119t, 120
- age and race in choice of, 238-239
- aliskiren with, 171
- ARBs with, 149, 240t
- β -blockers vs, 76, 290t
- β -blockers with, 62, 122-126, 124-125, 130, 198
- in black patients, 63, 117, 153, 239, 248
- calcium channel blockers vs, 151-154, 245, 246, 289, 290t
- ALLHAT trial, 69-70, 130-140, 135-138, 177-178, 289
- STOP-Hypertension-2, 127-130, 131t
- calcium channel blockers with, 76, 109, 178, 185-186, 248, 254, 290t
- cardiovascular events and, 79, 160, 232, 235, 246, 289, 290t-291t
- central agonists with, 223
- combination medications, 249, 250t, 252t
- combination therapy, 144, 244, 249-254
- in congestive heart failure, 62, 128-130, 131t, 132, 239, 245, 279
- contraindications and cautions, 146, 237t, 238t, 240t
- coronary heart disease and, 116, 126-127, 128t, 150, 232-233
- in diabetes, 72t, 120, 151-154, 235, 239, 246, 289
- ABCD study, 152-153, 153t
- CAPPP study, 122-126, 124-125, 147
- FACET study, 151-152, 290t
- new-onset diabetes, 104t, 105, 149, 163, 233
- UKPDS study, 101, 126-127, 128t
- diuretics vs, 70, 76, 291t
- diuretics with, 87-88, 93, 107, 109, 114, 120, 146, 147, 245, 248, 249, 250t
- dosage, 81, 119t, 144
- duration of action, 117
- effectiveness of, 117-120, 232
- in elderly patients, 158, 235, 285
- heart failure and, 72t, 116, 120
- CHD, 62, 128-130, 131t, 132, 239, 245, 279
- HOPE and HOPE-TOO studies, 79, 121-122, 123
- hydrochlorothiazide with, 93, 122-126, 124-125
- hyperglycemia risk, 107
- indications for, 72t, 77t, 120, 236t, 244
- as initial therapy, 63, 64t, 75, 107, 120, 154, 233, 242, 249-254
- insulin resistance and, 147-148, 149
- ischemic heart disease and, 120, 191
- left ventricular hypertrophy and, 248
- lipid levels and, 96
- monotherapy with, 63, 117, 147, 154
- morbidity/mortality outcomes with, 290t-291t
- myocardial infarction and, 72t, 120, 121-122, 123, 233, 235, 244
- physiologic effects, 117, 119t, 243t
- post-myocardial infarction, 72t
- potassium levels and, 91-93, 117
- in pregnancy, 146, 238t
- renovascular function/disease, 79, 146-151, 233, 289
- monitoring for, 146

side effects, 117-120, 119t, 144-146
 cough, 119t, 144-145
 loss of taste, 117, 145
 stroke protection with, 72t, 75t, 114
 tolerability, 80
 trials and studies, 120-144
 ADVANCE, 151
 ALLHAT, 69-70, 130-140, 134t, 135-138
 ANBP 2, 140-142, 141
 CAPP, 122-126, 124-125, 147
 HOPE, 121-122, 147-148
 HOPE-TOO, 122, 123
 HOT, 181t
 PROGRESS, 142-144, 143
 STOP-Hypertension-2, 127-130, 129, 131t, 132
 UKPDS, 101, 126-127, 128t

Acetubutolol (Sectral), 64t, 194, 195, 196t-197t

Aceon. See *Perindopril*.

Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation (ADVANCE) Trial, 151

Adalat CC. See *Nifedipine*.

Adrenalectomy, 17

Adrenergic blockers. See *α_1 -Blockers*; *β -Blockers*.

ADVANCE trial, 151

Aerobic exercise, 46-47

African American Study of Kidney Disease and Hypertension (AASK), 79, 153, 188-190, 200-201, 290t. See also *Black patients*.

Age, initial drug selection and, 238-239, 240t-241t. See also *Elderly patients*.

Albuminuria, 78-79

Alcohol intake/moderation, 34t, 38t, 45-46, 49

Aldactazide, 253t

Aldactone (spironolactone), 85t, 93-95, 254

Aldomet. See *Methyldopa*.

Aldoril, 113t, 252t

Aldosterone antagonists, 85t, 86, 93-95. See also *Renin-angiotensin-aldosterone (RAAS) inhibitor*.
 action mechanisms, 95, 118
 combined with other diuretics, 93, 242
 indications for, 71, 72t, 244
 as initial therapy, 242
 post-myocardial infarction, 72t
 tolerability, 93

Aldosteronism, resistant hypertension and, 264t

Aliskiren (Tekturna), 63, 88, 171, 172t, 255
 combination therapy, 171
 dosage, 172t

ALLHAT (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial), 63-65, 69-70, 76, 130-140, 135-138, 280
 α_1 -blockers and cardiac events on, 288
 black population in, 69-70, 130, 133-136, 137
 cardiovascular disease events, 110t
 CCBs on, 177
 coronary heart disease events, 111t, 148-149, 150, 235, 284, 289
 diabetes, new-onset, 97, 103t-105t, 104t, 148, 149, 163
 diabetic population in, 130, 289
 diuretic outcomes, 115-116, 138
 diuretics and cholesterol levels, 96-97, 99t
 diuretics and glucose metabolism, 103t
 diuretics and potassium levels, 91-93
 doxazosin on, 133, 217
 flaws in, 139
 heart failure on, 133, 136, 138, 217, 291t
 initial drugs, choice/comparison of, 68-70
 morbidity/mortality outcomes data, 135-138, 235, 290t-291t
 myocardial infarction (nonfatal) and CHD deaths, 135, 186, 292

potassium levels in, 91-93
 strokes on, 133-136, 137
 summary of outcomes, 138, 232-233, 284, 290t-291t
 treatment failure on, 133, 217

Allopurinol, 92t, 108

α -blockers, nonselective, 215

α_1 -Blockers, 215-218, 218t. See also *α_1 - β -Blockers*; *β -Blockers with vasodilating properties*; *specific drugs*.
 action mechanism, 215, 216
 as add-on therapy, 76, 77t
 adverse effects and discontinuation, 216, 217
 ALLHAT trial, 130, 133, 288, 291t
 angina and, 217
 β -blockers with, 210t
 β -blockers with vasodilating properties vs., 209
 cardiac events and, 69, 291t
 contraindications, 236t
 diabetes and, 101
 diuretics vs., 69, 217, 246, 291t
 dosage, 216-217, 218t
 drugs in this category, 215, 218t
 effectiveness of, 215, 246
 in elderly men, 91, 217
 heart failure incidence with, 133, 217
 indications for, 215, 217, 236t, 240t
 as initial drug, 63, 64t, 77t
 ESH/ESC recommendation, 77t
 not preferred for, 76, 80, 217, 288
 lipid levels and, 217
 morbidity/mortality outcomes with, 291t
 myocardial infarction and, 233
 nonselective α -blockers, 215
 for pheochromocytoma, 215
 physiologic effects, 211t, 218t, 243t
 for prostatic hypertrophy, 91, 217, 240t
 selective, 215, 218t
 side effects, 215-216
 as third- or fourth-step medications, 217

α_1 - β -Blockers, 210t. See also *β -Blockers with vasodilating properties*.
 carvedilol, 209, 210t, 212-213, 240t
 congestive heart failure and, 212-213, 241, 279
 indications for, 236t, 241
 labetalol, 209, 210t, 211, 212
 physiologic effects, 243t

α_2 -agonists, cautions for, 237t

α_2 -receptors, central agonists and, 223

Altace (ramipril), 79, 119t

Ambulatory blood pressure monitoring (ABPM), 26-28, 28t

Amiloride (Midamor), 85t

Amiloride with hydrochlorothiazide (Moduretic), 86, 252t

Amlodipine (Norvasc), 175t, 254. See also *Calcium channel blockers (CCBs)*.
 AASK study, 79, 153, 188-190, 200-201
 action mechanisms, 173, 175t, 176
 aliskiren with, 171
 ALLHAT trial, 130-140, 135-138, 177
 ASCOT trial, 177, 187-188, 189, 284
 in black patients, 79, 153, 188-190, 200-201
 cardiovascular/coronary heart disease events, 110t-111t, 148-149, 150, 178
 dosage, 175t
 FACET study, 78, 151-152, 290t
 IDNT study, 78-79, 164-166, 166
 lipid levels and, 96
 side effects, 175t
 TOMHS study, blood pressure change on, 64t
 VALUE trial, 76, 100, 104t, 169, 170t, 177, 188, 190

- Amlodipine with atorvastatin (Caduet), 252t
 Amlodipine with benazepril (Lotrel), 252t
 Amlodipine with olmesartan (Azor), 251t, 255
 Amlodipine with valsartan (Exforge), 251t
 ANBP 2 (Australian National Blood Pressure) study, 70, 140-142, 141, 280
 diabetes, new-onset, 104t
 drugs compared, 140
 flaws in, 140-142
 morbidity/mortality outcome data, 291t
 Angina pectoris
 α_1 -blockers and, 217
 β -blockers and, 195, 198, 236t, 239, 240t
 CCBs in, 184, 188, 236t, 239, 240t
 drug indications and contraindications in, 236t, 239
 Angioedema
 ACE inhibitors and, 145
 ARBs and, 155
 Angioplasty, SHEP study, 283
 Angiotensin-converting enzyme inhibitors. See *ACE (angiotensin-converting enzyme) inhibitors*.
 Angiotensin II, 117, 118, 120, 146
 β -blockers and, 193
 renin inhibitors and, 171
 Angiotensin II receptor blockers (ARBs), 155-170, 156t. See also *specific drugs*.
 ACE inhibitors with, 149, 240t
 action mechanisms/sites, 118, 155-157
 age and race in choice of, 238-239
 aliskiren with, 171
 β -blockers vs, 246, 291t
 in black patients, 159, 239, 248
 calcium channel blockers vs, 177, 245, 291t
 calcium channel blockers with, 109, 251t
 cardiovascular morbidity and mortality and, 79, 160, 235, 246, 292
 combination medications, 250t-251t, 254-255
 combination therapy, 158-159, 160, 249
 congestive heart failure and, 62, 72t, 245, 279
 contraindications and cautions, 157, 237t, 238t, 240t
 diabetes, 72t, 163-168, 239
 new-onset diabetes, 100, 104t, 105, 148, 149, 163, 233, 246
 prevention, 149
 diuretics with, 88, 93, 107, 109, 158, 242-245, 245, 249, 250t-251t
 dosage, 81, 156t, 157-158
 drugs in this category, 155, 156t
 effectiveness of, 155, 160
 in elderly patients, 158, 160, 168-169, 285
 heart failure, 160-161
 hydrochlorothiazide with, 158-159
 indications for, 72t, 155-160, 244
 specific indications, 72t, 77t, 160-162
 heart failure, 160-161
 left ventricular hypertrophy, 79, 160, 161-162, 162t, 167
 as initial therapy, 63, 75, 107, 159, 160, 242
 adding a diuretic to, 245
 for diabetics, 233
 ESH/ESC recommendation, 77t, 284, 288
 JNC 7 recommendation, 77t
 monotherapy with, 158, 159
 morbidity/mortality outcomes with, 291t
 myocardial infarction and, 169, 170t, 245, 246
 nitric oxide and, 157
 physiologic effects, 155-157, 156t, 243t
 potassium levels and, 157
 in pregnancy, 157, 238t
 in prehypertension, 23
 renal disease and, 78-79
 side effects, 155, 156t
 stroke and, 72t, 79, 246
 tolerability, 80, 155, 167
 trials and studies, 78-79, 158
 ALLHAT, 163
 CHARM, 104t, 161
 ELITE 2, 161
 IDNT, 164-166, 166
 IRMA 2, 78-79, 166-167, 168
 LIFE, 161-162, 162t, 163
 PRIME, 158
 RENAAL, 158, 163-164, 165
 SCOPE, 104t, 163, 168-169, 179
 Val-HeFT, 161
 VALUE, 163, 169, 170t
 Anglo-Scandinavia Cardiac Outcomes Trial (ASCOT), 73, 76, 104t, 148, 187-188, 189, 199, 232, 233
 Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial. See *ALLHAT*.
 Appropriate Blood Pressure Control in Diabetes (ABCD), 78, 152-153, 153t, 290t
 Apresoline. See *Hydralazine*.
 ARBs. See *Angiotensin II receptor blockers*.
 Arrhythmias, CCBs indicated for, 176
 ASCOT (Anglo-Scandinavia Cardiac Outcomes Trial), 73, 76, 177, 187-188, 189, 199, 280
 congestive heart failure outcomes, 232
 coronary heart disease outcomes, 233
 diabetes, new-onset, 104t, 148
 drugs compared, 187, 284
 morbidity/mortality outcome data, 291t
 Aspirin, for CV protection in hypertensive patients, 183
 Asthma
 β -blockers in, 194, 201-204, 203t, 240t
 central agonists in, 226
 drug selection for initial therapy, 239
 Atacand (candesartan), 156t
 Atacand HCT, 112t, 158, 250t
 Atenolol (Tenormin), 196t-197t, 206
 action mechanism, 194, 196t
 ALLHAT study, 130
 ASCOT trial, 187-188, 189
 diabetes, new-onset, 186
 in elderly patients, 283
 INVEST study, 185-186
 lipid solubility, 198
 pulmonary side effects, 201
 UKPDS study, 126-127, 128t
 Atenolol with chlorthalidone (Tenoretic), 112t, 251t
 Atherosclerosis
 isradipine and (MIDAS study), 290t
 metoprolol and (MAPHY study), 98t, 198
 verapamil and (VHAS study), 96, 184-185, 290t
 Atorvastatin, with amlodipine (Caduet), 252t
 Atrioventricular conduction
 β -blockers and, 204
 calcium channel blockers and, 176
 Augmentation index, 30
 Australian National Blood Pressure Study (ANBP 2), 70, 140-142, 141, 282t
 new-onset diabetes, 104t
 Autoimmune disorders, central agonists and, 224t, 225
 Avalide, 112t, 158, 250t
 Avapro. See *Irbesartan*.
 Azor, 251t, 255
 Behavioral Risk Factor Surveillance Survey (BRFSS), 293-295, 295t
 Benazepril (Lotensin), 119t, 254
 Benazepril with thiazide (Lotensin HCT), 112t, 250t

Bendroflumethiazide with nadolol (Corzide), 113t, 206, 251t
 Benicar (olmesartan), 156t, 157
 Benicar HCT, 113t, 158, 251t
 Benson relaxation response technique, 47, 48t
 β -Blockers, 193-207, 196t-197t. See also α_1 - β -Blockers; β -Blockers with vasodilating properties; specific drugs.
 ACE inhibitors vs, 76, 126-130, 128t, 129, 131t, 290t
 ACE inhibitors with, 122-126, 124-125, 130
 action mechanisms, 193-195, 196t-197t
 as add-on therapy, 80, 198
 age and race in choice of, 238-239
 in ALLHAT trial, 130
 in angina patients, 195, 198, 236t, 239, 240t
 ARBs vs, 79, 161-162, 162t, 291t
 asthma and, 194, 201-204, 203t
 in black patients, 200-201, 206, 239, 240t
 calcium channel blockers vs, 76, 177, 187-188, 189, 235
 calcium channel blockers with, 128-130, 131t, 176, 254
 cardioselective, 194, 196t-197t
 cardiovascular morbidity and mortality and, 62, 128-130, 131t, 200, 206, 207, 233, 290t-291t
 central agonists with, 223
 combination medications, 251t
 combination therapy, 206, 244, 245, 254
 in congestive heart failure, 62, 80, 128-130, 131t, 198, 279
 contraindications and cautions, 194, 201-204, 202t-203t, 205, 236t-237t, 239
 use as initial therapy, 75, 206, 240t
 depression and, 204
 in diabetes, 101, 126-127, 128t, 194
 LIFE study, 161-162, 162t, 201
 diuretics vs, 291t
 diuretics with, 88, 93, 109, 206, 245, 246, 248, 251t, 290t
 dosage, 196t-197t
 drugs in this category, 196t-197t
 effectiveness of, 80, 195, 198, 206-207
 in elderly patients, 198, 199, 206, 207, 283
 hyperglycemia risk, 107
 hypoglycemia and, 203t, 205
 indications for, 72t, 77t, 120, 198, 236t, 239, 240t, 241, 244
 as initial therapy, 63, 64t, 207, 233, 240t, 254
 ESH/ESC recommendation, 77t
 JNC 6 recommendation, 206-207, 232
 JNC 7 recommendation, 77t, 207
 recommendation against, 188, 201, 233
 with intrinsic sympathomimetic action (ISA), 195, 196t-197t
 in ischemic heart disease, 80, 127, 199, 206, 233
 lipid levels and, 203t, 205, 234, 241
 lipid solubility, 195-198
 metabolic changes with, 193, 203t, 205
 for migraine headaches, 237t
 monotherapy with, 206
 morbidity/mortality outcomes with, 233, 290t-291t
 myocardial infarction and, 72t, 188, 199-200, 200t, 207, 241, 244, 283
 in peripheral vascular occlusive disease, 236t
 physiologic effects, 193-194, 196t-197t, 243t
 renal blood flow changes, 205-206
 as second-step therapy, 198-201
 side effects, 196t, 201-204, 202t-203t
 bradycardia, 202t, 204
 cardiac, 204
 cold hands/Raynaud's phenomenon, 202t
 dyspnea/asthma flare-up, 203t
 fatigue, 202t, 204
 hypertriglyceridemia, 203t, 205
 hypoglycemia, 203t, 205
 insomnia/bizarre dreams, 202t, 204
 metabolic, 193, 203t, 205
 pulmonary, 201-204
 renal blood flow changes, 205-206
 sexual dysfunction, 203t
 stroke and, 78, 79, 233
 therapeutic recommendation summary, 206-207
 tolerability, 201
 trials and studies, 198-201
 AASK, 200-201
 ALLHAT trial, 130
 ASCOT, 199
 CAPP, 122-126, 124-125, 130
 HAPPHY, 198
 LIFE study, 161-162, 162t, 201
 MAPHY, 198
 MRC, 198, 201
 STOP-Hypertension-2, 198-199
 TOMHS, 204
 UKPDS, 200, 207
 types of, 194-198, 196t-197t
 with vasodilating properties, 75-76, 193
 without vasodilating properties, 193
 β -Blockers with vasodilating properties, 209-214, 210t. See also β -Blockers; specific drugs.
 as add-on therapy, 211
 adverse reactions, 210t, 211
 antioxidant properties, 210t, 211t, 212-213
 in black patients, 210t, 212
 cardiovascular morbidity and mortality, 212
 combined with diuretic, 211, 212
 in congestive heart failure, 212-213
 contraindications and cautions, 212
 in diabetes, 213
 dosage, 210t, 211
 drugs in this category, 209, 210t
 duration of action, 212
 effectiveness of, 212
 in elderly patients, 212
 GEMINI study, 213
 glycosylated hemoglobin with, 213
 hypertensive crisis, treatment of, 212
 as initial therapy, 288
 JNC 7 recommendation, 211
 physiologic effects, 209, 210t-211t, 243t
 specific indications for, 211, 212, 244
 Betaxolol, 194
 Biofeedback/relaxation programs, 47-48, 48t
 Bisoprolol with thiazide (Ziac), 112t, 251t
 Bisoprolol (Zebeta), 196t-197t
 action mechanism, 194, 196t
 cardiovascular events and, 200
 congestive heart failure and, 279
 pulmonary side effects, 201
 side effects, 196t
 Black patients
 α_1 - β -blockers in, 210t
 AASK study, 79, 153, 188-190, 200-201
 ACE inhibitors in, 63, 117, 153, 239, 240t, 248
 in ALLHAT trial, 69-70, 130, 133-136, 137
 amlodipine in, 79, 153, 188-190, 200-201
 ARBs in, 159, 239, 240t, 248
 β -blockers in, 200-201, 206, 239, 240t
 β -blockers with vasodilating properties in, 210t, 212, 240t
 calcium channel blockers in, 80, 153, 177, 188-190, 239
 combination therapy in, 248
 decline in mortality rates, stroke/CHD, 271, 272-273

dihydropyridines in, 177

diuretics in, 63, 80, 88, 239, 241t, 248

drug selection for, 63-65, 239, 243t

- preferred initial therapy, 80, 239
- effectiveness of specific antihypertensive drugs in, 243t
- kidney disease in, 79
- sodium restriction/salt sensitivity in, 39, 40

Blocadren. See *Timolol*.

Blood chemistries, in initial evaluation, 28-29, 29t

Blood pressure (BP)

- ambulatory monitoring (ABPM), 26-28, 28t
- cardiovascular risk and, 17, 19-21, 23
- central vs peripheral measurement, 30-31
- circadian rhythm of, 27
- coffee/caffeine intake and, 49-50
- diastolic. See *Diastolic blood pressure (DBP)*.
- finger BP recorders, 28
- goal levels, 53, 65-66
 - diabetic patients, 65, 292-293
 - elderly patients, 285
- home monitoring, 26, 27-28
- optimal adult, JNC 7 recommendation, 21, 22t
- reduction with lifestyle modifications, 38-40, 38t, 46, 47
- risk stratification, 55t
- systolic. See *Systolic blood pressure (SBP)*.

Blood Pressure Lowering Treatment Trialists Collaboration, 73, 127-128

Body weight, ideal, 34-35, 35t, 36, 36t, 39. See also *Obesity; Weight loss*.

Bradycardia

- β -blockers and, 195, 202t, 204, 240t
- drug contraindications for, 236t, 240t

Bradykinin levels

- ACE inhibitors and, 117, 118
- ARBs and, 155

Bumetanide (Bumex), 85t, 114-115, 241t

Bumex (bumetanide), 85t, 114-115, 241t

Bystolic. See *Nebivolol*.

Caffeine intake, 49-50

Calan. See *Verapamil*.

Calcium

- dietary intake/supplementation, 42, 49
- hypercalcemia, diuretic-induced, 92t, 108-109

Calcium channel blockers (CCBs), 173-191, 174t-175t, 175t, 178. See also

- Dihydropyridine CCBs; Nondihydropyridine CCBs; specific drugs*.

ACE inhibitors vs, 151-154, 245, 290t

- ALLHAT trial, 69, 130-140, 135-138, 177-178, 289
- STOP-Hypertension-2 study, 127-130, 131t, 132

ACE inhibitors with, 76, 109, 178, 248, 254, 290t

- ASCOT trial, 187-188

action mechanisms, 173-176, 174t-175t

adverse reactions, 174t-175t, 183-184

age and race in choice of, 239

aliskiren with, 171

ALLHAT trial, 69, 130-140, 134t, 135-138, 289

in angina patients, 184, 188, 236t, 239, 240t

ARBs vs, 245

ARBs with, 109, 248, 251t, 254

β -blockers vs, 76, 177, 187-188, 189, 235

β -blockers with, 128-130, 131t, 176, 254

in black patients, 80, 153, 177, 188-190, 239

cardiovascular morbidity/mortality and, 71-73, 128-130, 131t, 132, 152, 153t, 178, 187-188, 232, 235, 290t, 292

central agonists with, 223

combination medications, 252t, 254-255

combination therapy, 178, 244

congestive heart failure (CHF) and, 176, 186, 232, 292

contraindications and cautions, 176, 183, 236t

coronary heart disease (CHD) and, 72t, 178, 184, 232-233

diabetes and, 72t, 79, 101, 144, 180-183, 235

- ABCD study, 78, 152, 153t
- diabetes, new-onset, 149
- FACET study, 151-152
- HOT trial, 180-183
- SHEP study, 179
- Syst Eur trial, 179
- VALUE trial, 100, 149

dihydropyridines, 173, 175t, 176-178

diuretics vs, 69, 76, 109, 184, 246, 289, 290t

diuretics with, 88, 93, 109, 177, 184-185, 242-245

dosage, 174t-175t

drugs in this category, 174t-175t

effectiveness of, 177, 232

in elderly patients, 76, 177, 178-179, 235, 240t, 285

hyperglycemia risk, 107

indications for, 72t, 77t, 236t, 240t, 244

as initial therapy, 63, 64t, 75, 179, 233, 242-245

- ESH/ESC recommendation, 77t, 284, 288
- JNC 7 recommendation, 77t

ischemic heart disease and, 176, 184

for left ventricular hypertrophy, 248

lipid levels and, 96

long-acting formulations, 176, 183, 184-185

for migraine headaches, 237t

monotherapy with, 177, 179

morbidity/mortality outcomes with, 290t-291t

myocardial infarction and, 169, 170t, 233, 292

nondihydropyridines, 173, 174t, 176

physiologic effects, 173-176, 174t-175t, 243t

potassium levels and, 91-93

recently introduced/under study, 254-255

renal disease and, 233

short-acting formulations, 176, 183

side effects, 174t-175t, 176, 178, 183-184, 186-187

stroke and, 73, 79, 137, 245, 289

Syst Eur, 178-179

treatment program summary, 190-191

trials and studies, 178-190

- AASK, 188-190
- ALLHAT, 177-178, 186
- ASCOT, 177, 187-188, 189, 232
- HOT, 180-183, 181t-182t
- INSIGHT, 185, 186-187
- INVEST, 104t, 185-186, 290t
- NORDIL, 185, 186, 279-280, 290t
- STOP-Hypertension-2, 127-130, 131t, 132
- VALUE, 177

CALM (Candesartan and Lisinopril Microalbuminuria) study, 163

Candesartan and Lisinopril Microalbuminuria (CALM) study, 163

Candesartan (Atacand), 156t

- CALM study, 163
- dosage, 156t, 157
- SCOPE study, 104t, 163, 168-169, 179, 284

Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) trial, 104t, 161

Candesartan with thiazide (Atacand HCT), 112t, 158, 250t

Capoten (captopril), 119t

Capozide, 112t, 249, 250t

CAPP. See *Captopril Prevention Project*.

Captopril (Capoten), 119t

- UKPDS study, 71, 76, 101, 126-127, 128t

- Captopril Prevention Project (CAPPP), 122-126, 124-125, 279-280
 CV event reduction, 71-73, 78
 diabetes, new-onset, 104t, 105
 drugs compared, 122-123
 metabolic syndrome, ACE inhibitors and, 147
 morbidity/mortality outcome data, 290t
 Captopril with hydrochlorothiazide (Capozide), 112t, 249, 250t
 Cardene SR (nicardipine SR), 175t
 Cardiac arrhythmias, nondihydropyridines indicated for, 176
 Cardiac function, drug indications and contraindications, 236t
 Cardiovascular morbidity and mortality, 235, 271-292, 272-273, 274t, 282t, 290t-291t. See also *specific drugs and conditions*.
 Cardizem CD, 174t. See also *Diltiazem*.
 Cardizem LA, 174t. See also *Diltiazem*.
 Cardura. See *Doxazosin*.
 Carotid-femoral pulse wave velocity studies, 32
 Carvedilol (Coreg, Coreg CR), 209, 210t, 212-213
 antioxidant properties of, 210t, 211t, 212-213
 in black patients, 212
 in congestive heart failure, 212-213, 241, 279
 in diabetes, 213
 dosage, 210t
 duration of action, 212
 in elderly patients, caution for, 212
 GEMINI study, 213
 glycosylated hemoglobin with, 213
 indications and contraindications for, 236t, 240t, 241
 insulin sensitivity and, 213
 ischemic heart disease and, 213
 physiologic effects, 210t
 side effects, 209-211, 210t
 Catapres. See *Clonidine*.
 Catecholamines
 alcohol and, 46
 α_1 -blockers and, 215
 initial evaluation and, 29t
 nicotine and, 49
 vasodilators and, 227
 CCBs. See *Calcium channel blockers (CCBs)*.
 Central agonists, 223-226, 224t. See also *specific drugs*.
 Central aortic pressure (CAP), 30-31, 32
 Central nervous system, β -blockers and, 204
 Cerebrovascular incidents. See *Stroke; Transient ischemic attacks*.
 CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) trial, diabetes, new-onset, 104t, 161
 CHF. See *Congestive heart failure (CHF)*.
 Children
 hypertension diagnosis in, 30
 lifestyle modifications and, 41
 sodium restriction and, 41
 Chlorothiazide (Diuril), 84t
 hemodynamic effects, 88
 Chlorthalidone, 83, 84t. See also *ALLHAT; Diuretics*.
 ALLHAT trial, 91, 96, 110t-111t, 130-140, 135-138
 blood pressure change in TOMHS study, 64t
 cardiovascular/coronary heart disease events, 110t-111t, 115, 150
 CCBs vs., 184-185
 diabetes, new-onset, 105t
 dosage, 84t, 242
 drug combinations with, 112t, 252t
 duration of action, 83, 84t
 hydrochlorothiazide vs., 115-116
 hyperuricemia/gout with, 108
 hypokalemia and, 91
 as initial therapy, 242
 lipid levels and, 96
 Cholesterol level. See also *Hyperlipidemia; Hypertriglyceridemia; Lipid levels*.
 diuretics and, 95-97, 98t-99t, 100, 234
 effects of specific antihypertensive drugs on, 243t
 Chronic obstructive pulmonary disease (COPD), 201, 203t, 240t
 Circadian rhythm of blood pressure, 27
 Clinical trials. See *Trials and studies*.
 Clonidine (Catapres), 130, 223, 224t, 225-226. See also *ALLHAT; Central agonists*.
 Clonidine with chlorthalidone (Clorpres), 112t, 252t
 Clorpres, 112t, 252t
 Coarctation of aorta, resistant hypertension and, 266t
 Coffee consumption, blood pressure and, 49-50
 Cognition, in elderly people, 104t, 163, 168-169, 179
 Combination therapy. See *Drug treatment of hypertension, combination therapy*.
 Congestive heart failure (CHF). See also *Cardiovascular (CV) risk; Heart disease*.
 α - β -blockers and, 240t, 241, 279
 ACE inhibitors and, 62, 128-130, 131t, 132, 239, 245, 279
 ACE inhibitors with ARBs and, 240t
 ALLHAT outcomes, 69, 289
 ARBs and, 62, 160-161, 239, 245, 279
 β -blockers and, 62, 80, 128-130, 131t, 198, 240t, 241, 279
 β -blockers with vasodilating properties and, 212-213
 carvedilol and, 240t, 241, 279
 CCBs and, 176, 186, 232, 245, 292
 combination drug treatment for, 62
 decline in, 273, 279
 digitalis treatment, 120, 279
 diuretics and, 232, 239, 246, 279, 289
 drug therapy/drug selection and, 239, 245, 282t, 283
 in elderly patients, treatment outcomes, 281-284, 282t-283t
 long-term antihypertensive drug treatment and, 60-62, 61
 nondihydropyridines and, 176
 prevention of, 279
 reduction with therapy, 276-279, 278t
 sodium restriction in, 40
 Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial, 60, 133, 280
 CONVINCE trial, 60, 133, 280
 COPD (chronic obstructive pulmonary disease), 201, 203t, 240t
 Coreg/Coreg CR. See *Carvedilol*.
 Corgard (nadolol), 196t-197t, 198
 Coronary artery bypass graft, SHEP study, 283
 Coronary artery disease, studies of, 282t
 Coronary heart disease (CHD)
 ACE inhibitors and, 116, 126-127, 128t, 148-149, 150, 232-233
 on ALLHAT, 76, 111t, 135, 148-149, 150, 235, 284, 289, 289
 calcium channel blockers and, 178, 184, 232-233
 decline in, 271, 272, 273, 274t
 diabetes as equivalent to, 58-59
 diuretics and, 232-233
 drugs indications in, 72t
 in elderly patients, treatment outcomes, 281, 282t
 initial drug selection and, 244
 initiation of hypertension treatment and, 51-52, 53
 morbidity and mortality from, 271, 273, 274t
 on ALLHAT, 111t, 135, 289, 289
 long-term antihypertensive drug treatment and, 61
 Corzide, 113t, 206, 251t
 Cough, as ACE inhibitor side effect, 119t, 144-145
 Covera. See *Verapamil*.
 Cozaar. See *Losartan*.
 Cushing's syndrome, resistant hypertension and, 265t
 Darusentan, 255
 DASH (Dietary Approaches to Stop Hypertension) diet, 36, 38t, 45
 DASH (Dietary Approaches to Stop Hypertension) study findings, 40

DBP. See *Diastolic blood pressure (DBP)*.

Demadox (torsemide), 85t, 114-115, 241t
for vasodilator-induced fluid accumulation, 229

Depression
β-blockers and, 204
central agonists and, 225
drug contraindications and cautions, 237t
reserpine and, 219-220, 221t

Diabetes. See also *STOP-Hypertension-2*.
ACE inhibitors in, 81, 120, 122, 123, 125, 126-127, 128t, 147-148, 152-154, 235, 246
ACE inhibitors with ARBs in, 239-241, 240t
ARBs in, 106, 149, 159, 161-162, 162t, 163-168, 233, 246, 292
β-blockers in, 126-127, 128t, 194, 200, 203t, 205, 207, 240t
β-blockers with vasodilating properties, recommendation for, 213
blood pressure goal in, 65, 292-293
calcium channel blockers in, 79, 101, 144, 179, 180-183, 182t, 235
cardiovascular risk and, 58-59
 blood pressure level and, 180-182, 182t
 carvedilol in, 213
central agonists in, 226
combination therapy in, 70, 75, 77t, 182
contraindicated drugs, 239, 240t
as coronary heart disease (CHD) equivalent, 58-59
diuretics in, 74, 93, 97-107, 104t-105t
drug therapy in, 58-59, 239-241, 244
hypokalemia and, 93
insulin reaction, β-blockers and, 194, 205
insulin resistance, diuretics and, 92t, 97-108, 102t-103t
insulin sensitivity, β-blockers with vasodilating properties and, 213
lipid abnormalities and monitoring, 59
nephropathy
 ACE inhibitors and, 239, 240t
 ARBs and, 164-166, 166, 168, 239, 240t
 drug therapy in, 239-241
 IDNT trial, 78-79, 164-166, 166
 IRMA-2 study, 168
 resistant hypertension case study, 257-258
neuropathy, ACE inhibitors and, 149-151
new-onset, 97-107, 104t-105t, 148, 149, 233
 ACE inhibitors and, 122, 126, 148, 233
 in ALLHAT, 101, 103t-105t
 antihypertensive drugs and, 79
 ARBs and, 163, 233, 246
 β-blockers and, 205
 diuretics and, 97-107, 104t-105t
RAAS inhibitors and, 80, 127, 144, 159-160
target blood pressure, 182
type 1 (insulin-dependent), drug indications and cautions, 237t
type 2, drug indications and cautions, 237t
white-coat hypertension and, 25

Diamicron MR, 151

Diastolic blood pressure (DBP)
CV risk and, 19-20, 20
goal, elderly patients, 285, 286
J-curve hypothesis and, 67-68
as prognostic indicator, 25
safe reduction levels for, 67-68, 296
thresholds for hypertension definition/treatment, 28t, 51-52

Dibenzylamine (phenoxybenzamine), 215

Dietary Approaches to Stop Hypertension (DASH) diet, 36, 38t, 45

Dietary Approaches to Stop Hypertension (DASH) study, 40

Difficult to control hypertension, volume control and, 31. See also *Resistant hypertension*.

Digitalis
β-blockers and, 198
heart failure treatment, 120, 279
hypokalemia in patients on, 93

Dihydropyridine CCBs, 173, 175t, 176-178. See also *Calcium channel blockers (CCBs)*.
action mechanisms, 173, 175t
in black patients, 178
combination therapy, 178
contraindications and cautions, 176, 183
coronary heart disease and, 178, 184
dosage, 175t
in elderly patients, 177, 178-179, 284
long-acting formulations, 176, 179, 180-183
morbidity/mortality outcomes with, 290t-291t
myocardial infarctions and, 169, 170t, 186
renal disease and, 289, 290t-291t
renal function and, 79
short-acting formulations, 176, 183
side effects, 175t, 176, 183
trials and studies
 AASK, 153, 188-190
 ALLHAT, 177
 ASCOT, 177, 187-188, 189
 HOT, 180-183, 181t-182t
 INDT, 291t
 INSIGHT, 78
 VALUE, 177, 188

Dilacor XR, 174t. See also *Diltiazem*.

Diltiazem (Cardizem, Dilacor, Tiazac), 174t
action mechanisms, 173, 174t
CAPPP study, 123
cardiovascular mortality/morbidity, 185, 186, 290t
dosage, 174t
effectiveness of, 78
indications and contraindications for, 176, 236t
NORDIL trial, 78, 104t, 185, 186, 279-280, 290t
side effects, 174t, 184, 186
thiazide with, 177

Diltiazem XR. See *Diltiazem (Cardizem, Dilacor, Tiazac)*.

Diovan. See *Valsartan*.

Diovan HCT, 113t, 251t

Direct vasodilators. See *Vasodilators*.

Diulo. See *Metolazone*.

Diupres, 113t, 220, 252t

Diuretics, 83-116, 84t-85t. See also *Loop diuretics; Thiazides; and specific drugs*.
α-blockers vs, 69, 217, 291t
ACE inhibitors vs, 76, 109, 291t
 ALLHAT trial, 69, 70, 130-144, 135-138, 291t
 ANBP 2 study, 140-142, 141, 291t
 ASCOT, 291t
ACE inhibitors with, 87-88, 93, 109, 114, 120, 146, 248, 249, 250t
action mechanisms, 86, 86-90, 88-89
aldosterone antagonists with, 85t, 86, 242
aliskiren with, 171
ALLHAT trial, 130-140, 134t, 135-138, 284
ARBs with, 88, 93, 107, 109, 158, 248, 249, 250t
β-blockers, 88, 93, 109, 206, 211, 232, 248, 251t, 290t, 291t
β-blockers with vasodilating properties with, 211, 212, 239
in black patients, 63, 80, 88, 239, 241t
calcium channel blockers, 69, 76, 88, 93, 109, 177, 184-185, 246, 290t
cardiovascular morbidity and mortality, 68-69, 76, 80, 109, 110t-111t, 232, 290t-291t
central agonists with, 223, 225
cholesterol level and, 95-97, 98t-99t, 100, 234
combination therapy, 80, 87-90, 93, 109, 212, 242-245, 244, 246
in congestive heart failure, 232, 239, 246
contraindications and cautions, 236t-237t, 240t
coronary heart disease (CHD) and, 232-233
in diabetes, 72t, 74, 93, 97-107, 104t-105t
dosage, 84t-85t, 87-88

dose-response curve, 87

drugs in this category, 84t-85t

duration of action, 84t-85t

effectiveness of, 84t-85t, 232, 241t

in elderly patients, 90, 93, 99t, 104t-105t, 241t

glucose metabolism and, 97-108, 102t-103t

in heart failure treatment, 71, 72t

hypercalcemia and, 92t, 108-109

hyperlipidemia/hyperglycemia and, 241

indications for, 72t, 77t, 236t, 240t

indoline derivatives, 83, 114

as initial therapy, 63, 64t, 68-70, 75, 109, 233, 238, 242, 244

for left ventricular hypertrophy, 248

lipid levels and, 92t, 95-97, 98t-99t, 234

loop, 83, 85t, 114-115

metabolic changes with, 91-109, 92t

monotherapy with, 87

morbidity/mortality outcomes with, 290t-291t

myocardial infarction and, 233, 246

in osteoporosis, 109, 241t

peripheral adrenergic inhibitors with, 219, 220

physiologic characteristics, 243t

potassium-sparing, 83, 85t, 86, 93

reserpine with, 219, 220

side effects, 90-109

- hypercalcemia, 92t, 108-109
- hyperlipidemia, 92t, 95-97, 98t-99t
- hyperuricemia, 92t, 108
- hypokalemia, 91-95, 92t
- insulin resistance, 92t, 97-108, 102t-103t
- renal disease, 109
- sexual dysfunction, 90-91
- strokes and, 142-144, 143, 232
- thiazide/thiazide-type, 83, 240t
- vasodilation and, 87

Diuril. See *Chlorothiazide*.

Dizziness

- α_1 -blockers and, 216, 218t
- β -blockers with vasodilating properties and, 209
- central agonists and, 223

Doxazosin (Cardura), 215, 218t. See also α_1 -Blockers.

action mechanism, 216

ALLHAT trial, 130, 133, 217, 291t

diuretic vs, 69

dosage, 216-217, 218t

effectiveness of, 215

heart failure incidence with, 133, 217, 291t

lipid levels and, 217

myocardial infarction and, 217

physiologic effects, 218t

for prostatic hypertrophy, 91

side effects, 215-216

as third- or fourth-step drug, 217

TOMHS study, 64t

DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication), 148

Drug treatment of hypertension, 53-82, 231-255. See also *specific drugs and drug types*.

Dyazide, 86, 242, 253t

DynaCirc CR. See *Isradipine*.

Dyrenium (triamterene), 85t

Dyslipidemia. See *Hyperlipidemia; Hypertriglyceridemia; Lipid levels*.

Dyspnea, β -blockers and, 203t

Echocardiogram, 29-30

Edema, peripheral, CCBs and, 175t, 178, 183

Elderly patients

- α_1 -blockers in, 217
- ACE inhibitors in, 76, 78, 129, 240t
 - as alternative or add-on therapy, 285
 - STOP-Hypertension-2 study, 127-130, 129, 131t, 132, 235
- ARBs in, 158, 160, 161, 168-169, 240t
 - as alternative or add-on therapy, 285
- β -blockers in, 198, 199, 206, 207, 281
 - as third- or fourth-step, 283
- β -blockers with vasodilating properties, 214
- calcium channel blockers in, 76, 177, 178-179, 235, 240t, 284, 285
- cognition in, 104t, 163, 168-169, 179
- combination therapy in, 285
- congestive heart failure in. See *Congestive heart failure*.
- contraindications and cautions, 242
- coronary heart disease (CHD) in, 281, 282t
- diabetes in, 105t, 106, 281
- diagnosis in, 30
- dihydropyridines in, 177, 178, 284
- diuretics in, 90, 93, 99t, 104t-105t, 241t, 281-283
 - as preferred initial therapy, 284-285
- drug therapy, 59, 65, 71, 76, 239, 242
- hypokalemia in, 93
- ischemic disease in, 206, 283
- isolated systolic hypertension in, 65, 90, 178-179, 259-261, 281, 284
- losartan in, 161
- percentage with hypertension, not treated, 21, 21
- prostatic hypertrophy, 91, 217
- sodium restriction/salt sensitivity in, 39-40
- therapeutic results in, 281-288, 282t, 283, 287t
- trials and studies, 281-286, 282t. See also *specific studies*.
 - ALLHAT, 284
 - ASCOT, 187-188, 189, 284
 - Australian, 282t
 - ELITE 2, 161
 - EWPHE, 98t, 102t, 282t
 - HDFFP, 282t
 - HYVET, 114, 287-288, 287t
 - MRC, 282t, 291t
 - SCOPE, 104t, 163, 168-169, 179, 284
 - SHEP, 281, 282t, 283
 - STOP-Hypertension-2, 127-130, 131t
 - Syst Eur, 71, 178-179, 282t, 284
 - TONE, 39-40
- very old patients, 286-288, 287t

ELITE 2 (Evaluation of Losartan in the Elderly-Part 2), ELITE 2, 161

Enalapril (Vasotec), 119t

- ABCD study, 152, 153t
- average blood pressure change in TOMHS study, 64t
- in combination therapy, 252t
- in diabetes, 163
- dosage, 119t
- as initial therapy, 63
- physiologic effects, 119t
- side effects, 119t

Enalapril with felodipine (Lexxel), 252t

Enalapril with hydrochlorothiazide (Vaseretic), 112t, 250t

Endothelin receptor antagonist (darusentan), 255

Eplerenone (Inspra), 85t, 93-95, 254

Eprosartan (Teveten), 156t

Eprosartan with thiazide (Teveten HCT), 112t, 158, 250t

ESH/ESC. See *European Societies of Hypertension and Cardiology*.

European Societies of Hypertension and Cardiology (ESH/ESC)

- on ACE inhibitors, 77t, 154
- on α -blockers, 77t

- on ARBs, 77t, 160
- on β -blockers, 201
- on CCBs, 77t, 179
- on combination therapy, 77t
- current recommendations, 77t
- on diuretics, 77t
- guidelines for monitoring/treatment (2007), 51-52, 54, 70, 77t, 245, 284
- hypertension classification, 24
- on initial therapy, 77t, 245, 284, 288
- prehypertension classification, 22-23
- European Working Party on High Blood Pressure in the Elderly (EWPHE) study, 98t, 102t, 282t
- Evaluation of Losartan in the Elderly-Part 2 (ELITE 2), 161
- EWPHE (European Working Party on High Blood Pressure in the Elderly) study, 98t, 102t, 282t
- Exercise, 46-47, 49
 - blood pressure reduction from, 38t, 46, 47
 - caloric expenditure in, 36, 37t
- Exforge, 251t
- FACET (Fosinopril vs Amlodipine Cardiovascular Events Trial), 78, 151-152, 290t
- Fat intake, 34t, 35-36, 44
- Fatigue
 - β -blockers and, 202t, 204
 - β -blockers with vasodilating properties and, 209
 - central agonists and, 223
- Felodipine (Plendil), 175t
 - action mechanisms, 173, 175t, 176
 - dosage, 175t
 - HOT trial, 180-183, 181t-182t
 - side effects, 175t, 180
- Felodipine with enalapril (Lexxel), 252t
- Fibric acid derivatives, drug therapy in diabetics, 59
- Fish oil intake, 44-45
- Fluid retention, vasodilators and, 227, 228t, 229
- Follow-up recommendations, 50-52, 236t-237t
- Fosinopril (Monopril), 119t
 - diuretic with, 112t, 250t
 - dosage, 119t
 - FACET trial, 78, 151-152, 290t
 - physiologic effects, 119t
 - side effects, 119t
- Fosinopril vs Amlodipine Cardiovascular Events Trial (FACET), 78, 151-152, 290t
- Fosinopril with thiazide (Monopril HCT), 112t, 250t
- Framingham Study, 19
- Furosemide (Lasix), 85t, 114-115
 - dosage, 85t
 - duration of action, 85t
 - indications for, 241t
 - for vasodilator-induced fluid accumulation, 229
- Garlic intake, 45
- GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives), 213
- Glucose metabolism. *See also Diabetes; Insulin resistance.*
 - α_1 -blockers and, 217
 - diuretics and, 97-108, 102t-103t
- Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI), 213
- Gout, 92t, 108, 241t
- Guanabenz, 225, 226
- Guanadrel (Hylorel), 219, 221t
- Guanethidine (Ismelin), 219, 221t
- Guanfacine (Tenex), 223-226, 224t. *See also Central agonists.*
- Gynecomastia, 254
- Hair growth, minoxidil and, 227, 228t, 229
- Hair loss, on β -blockers with vasodilating properties, 211
- HAPPHY (Heart Attack Primary Prevention in Hypertension) study, 98t, 102t, 198
- Harris poll, 293, 295t
- HCTZ. *See Hydrochlorothiazide (HCTZ; Hydrodiuril, Microzide).*
- HDFP (Hypertension Detection and Follow-up Program), 27, 66
 - diabetes, new-onset, 100, 105t
 - diuretics and cholesterol levels, 96, 98t, 100
 - diuretics and glucose metabolism, 102t
- HDL. *See High-density lipoprotein.*
- Headache
 - β -blockers with vasodilating properties and, 209
 - calcium channel blockers and, 175t, 183, 184, 186
 - as symptom of hypertension, 180
 - vascular (migraine), drug indications for, 237t
- Heart Attack Primary Prevention in Hypertension (HAPPHY) study, 98t, 102t, 198
- Heart attack. *See Myocardial infarction.*
- Heart disease. *See also Cardiovascular (CV) risk; Cardiovascular morbidity and mortality; Coronary heart disease (CHD); Left ventricular entries.*
 - ischemic, 67-68, 80, 127, 182t, 199, 206, 233. *See also Ischemic heart disease.*
- Heart failure
 - ACE inhibitors and, 72t, 116, 120
 - on ALLHAT, 133, 136
 - α_1 -blockers and, 133, 217
 - ARBs and, 72t, 160-161
 - congestive. *See Congestive heart failure.*
 - diuretics and, 80
 - doxazosin and, 133, 217
 - drug indications and contraindications in, 71, 72t, 244
 - Val-HeFT study of, 161
- Heart Outcomes Prevention Evaluation (HOPE). *See HOPE; HOPE-TOO.*
- Heart rate
 - effects of specific antihypertensive drugs on, 243t
 - increase, CCBs and, 183
 - rapid, drug indications and contraindications in, 236t
- High-density lipoprotein (HDL), 59, 95, 241-242
 - β -blockers and, 203t, 205, 241
 - effects of specific antihypertensive drugs on, 243t
- High-normal hypertension. *See Prehypertension.*
- Hirsutism, minoxidil and, 227, 228t, 229
- History of hypertension management, 219-220, 231
- Home monitoring of blood pressure, 26, 27-28
- HOPE (Heart Outcomes Prevention Evaluation), 79, 95, 121-122, 147-148, 280
- HOPE-TOO, 122, 123
- HOT (Hypertension Optimal Treatment) trial, 180-183, 181t-182t, 279-280
 - aspirin recommendation from, 183
 - blood pressure lowering on, 296
 - cardiovascular events and, 60, 68, 71-73, 180-183, 182t
 - impact on recommendations, 182
 - summary, 182t
- Hydralazine (Apresoline), 227-229, 236t, 228t, 238t. *See also Vasodilators.*
- Hydrochlorothiazide (HCTZ; Hydrodiuril, Microzide), 83. *See also Thiazides.*
 - ACE inhibitors with, 93, 122-126, 124-125
 - aliskiren with, 171
 - ARBs with, 93, 158-159, 249
 - β -blockers with, 93
 - CCBs vs, 184
 - chlorthalidone vs, 115-116
 - combination medications, 249, 250t-252t
 - combination therapy, 93, 158
 - dosage, 87, 242
 - duration of action, 83
 - as initial therapy, 242
 - side effects, 91, 94t, 108
 - ventricular ectopy with, 94t

- Hydrodiuril. See *Hydrochlorothiazide*.
- Hydropres, 113t, 220, 253t
- Hylorel (guanadrel), 219, 221t
- Hypercalcemia, diuretic-induced, 92t, 108-109
- Hyperdynamic circulation, 236t
- Hyperglycemia
 - ACE inhibitors and, 107
 - antihypertensive drugs and, 107
 - β -blockers and, 107
 - calcium channel blockers and, 107
 - diuretics and, 241
- Hyperlipidemia. See also *Cholesterol*; *Hypertriglyceridemia*; *Lipid levels*.
 - in ALLHAT, 96-97, 99t
 - in diabetes, 281
 - diuretics and, 92t, 95-97, 98t-99t, 241
 - omega-3 fatty acid intake and, 45
 - as risk factor, treatment initiation and, 22, 53
 - in SHEP, 281
- Hypertension Detection and Follow-up Program (HDFP), 27, 66
 - diabetes, new-onset, 100, 105t
 - diuretics and cholesterol levels, 96, 98t, 100
 - diuretics and glucose metabolism, 102t
- Hypertension in the Very Old Trial (HYVET), 114, 287-288, 287t
- Hypertension Optimal Treatment (HOT) trial, 180-183, 181t-182t, 279-280
 - ACE inhibitor in, 181t
 - aspirin recommendation from, 183
 - blood pressure lowering on, 296
 - cardiovascular events and, 60, 68, 71-73, 180-183, 182t
- Hypertensive crisis, 212
- Hyperthyroidism, resistant hypertension and, 265t
- Hypertriglyceridemia, β -blockers and, 203t, 205
- Hypertrophic cardiomyopathy, 236t
- Hyperuricemia, diuretic-induced, 92t, 108
- Hypoglycemia, β -blockers and, 203t, 205
- Hypokalemia, diuretic-induced, 91-95, 92t
- Hypotension, postural
 - α_1 -blockers and, 215, 216, 218t
 - β -blockers with vasodilating properties and, 209
 - peripheral adrenergic inhibitors and, 221t
- Hytrin. See *Terazosin*.
- HYVET (Hypertension in the Very Old Trial), 114, 287-288, 287t
- Hyzaar, 112t, 158, 249, 251t
- IDNT (Irbesartan Diabetic Nephropathy Trial), 78-79, 164-166, 166, 291t
- Indapamide (Lozol), 75, 84t, 108, 114, 142-144, 143, 287
- Inderal LA. See *Propranolol LA*.
- Inderide, 113t
- Inderide LA, 251t
- Indoline derivative diuretics, 83, 114
- InnoPran XL, lipid solubility, 195
- INSIGHT (International Nifedipine Gastrointestinal Therapeutic System Study
 - Intervention as a Goal for Hypertension Therapy), 78, 104t, 185, 186-187, 280, 290t
- Insomnia, β -blockers and, 202t, 204
- Inspira (eplerenone), 85t, 93-95, 254
- Insulin resistance
 - ACE inhibitors and, 147-148, 149
 - β -blockers and, 205
 - diuretics and, 92t, 97-108, 102t-103t
 - white-coat hypertension and, 25
- International Nifedipine Gastrointestinal Therapeutic System Study Intervention as a Goal for Hypertension Therapy. See *INSIGHT*.
- International Verapamil SR/Trandolapril Study. See *INVEST*.
- Intrinsic sympathomimetic action (ISA), 195, 196t-197t
- INVEST (International Verapamil SR/Trandolapril Study), 104t, 185-186, 290t
- Irbesartan (Avapro), 156t
 - dosage, 156t, 157
 - IDNT study, 78-79, 164-166, 166, 291t
 - IRMA 2 study, 78-79, 166-167, 168
 - PRIME study, 158
- Irbesartan Diabetic Nephropathy Trial (IDNT), 78-79, 164-166, 166
- Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients (IRMA 2), 78-79, 166-167, 168
- Irbesartan with thiazide (Avalide), 112t, 158, 250t
- IRMA 2 (Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients), 78-79, 166-167, 168
- ISA (intrinsic sympathomimetic action), 195, 196t-197t
- Ischemic heart disease
 - β -blockers and, 80, 127, 199, 206, 233
 - ACE inhibitors and, 120, 191
 - calcium channel blockers and, 176, 184
 - carvedilol and, 213
 - DBP reduction and, 67-68, 296
 - echocardiogram and, 29
 - in elderly patients, 206, 283
 - HOT trial, 182t, 296
- ISH. See *Isolated systolic hypertension (ISH)*.
- Ismelin (guanethidine), 219, 221t
- Isolated systolic hypertension (ISH), 20
 - elderly patients with, 65, 90
 - Syst Eur trial, 178-179, 284
- Isoptin. See *Verapamil*.
- Isradipine (DynaCirc CR), 175t
 - action mechanisms, 173, 175t, 176
 - dosage, 175t
 - MIDAS study of, 290t
 - side effects, 175t, 183
- J-shaped curve, 67-68
- JNC 6, drug treatment recommendations, 206-207, 232, 281
- JNC 7. See *Joint National Committee (JNC 7) recommendations*.
- Joint National Committee (JNC 7) recommendations, 21, 22t, 54, 55t
 - on ACE inhibitors with diuretic, 120
 - on alcohol intake, 45
 - on β -blockers, 207
 - diagnostic evaluation, 28-29, 29t
 - on drug therapy, 54, 55t, 232
 - on echocardiogram, 29
 - on hypertension classification, 21, 22t
 - on initial evaluation, 28-29, 29t
 - on magnesium supplementation, 44
 - optimal adult BP, 21, 22t
 - prehypertension classification, 22t
 - risk-factor categories, 55t
- Kerlone. See *Betaxolol*.
- Ketosis, 35
- Kidney disease. See also *Nephropathy*; *Renal entries*.
 - in blacks, 79
 - drug indications in, 72t
- Labetalol (Normodyne, Trandate), 209, 210t, 211
 - in black patients, 210t, 212
 - dosage, 210t, 211
 - in elderly patients, caution for, 212
 - hair loss, 211
 - for hypertensive crisis, 212
 - indications and contraindications for, 236t, 237t
 - physiologic effects, 210t
 - side effects, 211

- Lasix. See *Furosemide*.
- LDL (low-density lipoprotein), 59
- Left ventricular dysfunction, white-coat hypertension and, 25
- Left ventricular hypertrophy (LVH)
- ACE inhibitors and, 248
 - ARBs and, 79, 160, 161-162, 162t, 167, 246, 292
 - β -blockers and, 246, 248
 - calcium channel blockers and, 248
 - combination therapy and, 248
 - decline in occurrence of, 273
 - diuretics and, 248
 - drug therapy and, 61, 62, 276, 277t
 - commencement of therapy, 54, 248
 - echocardiogram as indicator of, 29
 - hydrochlorothiazide and, 94t
 - JNC recommendation, 248
 - LIFE study, 79, 161-162, 162t
 - masked hypertension and, 26
 - prevention of, 61, 62
- Left ventricular systolic function, CCBs and, 176
- Levatol (penbutolol), 196t-197t
- Lexxel, 252t
- LIFE (Losartan Intervention for End-point Reduction in Hypertension) study, 161-162, 162t
- β -blockers and, 161-162, 162t, 201
 - diabetes, new-onset, 104t, 105, 163
 - left ventricular hypertrophy, 161-162, 162t, 276
 - morbidity/mortality outcome data, 291t
- Lifestyle modifications, 33-52, 34t, 57t
- Lipid levels, 241-242. See also *Cholesterol*; *Hyperlipidemia*; *Hypertriglyceridemia*.
- β -blockers and, 203t, 205, 234, 241
 - in diabetes, 59
 - diuretics and, 231
 - management guidelines, 59
- Lipid solubility, of β -blockers, 195-198
- Lisinopril (Prinivil, Zestril), 69-70, 96, 110t-111t, 119t, 130-140, 135-138, 150, 163, 171
- Lisinopril with thiazide (Prinzide, Zestoretic), 112t, 250t
- Liver disease, drug indications and contraindications, 237t
- Loniten. See *Minoxidil*.
- Loop diuretics, 83, 85t, 86, 114-115, 237t, 241t. See also *specific drugs*.
- Lopressor. See *Metoprolol*.
- Lopressor HCT, 113t, 206
- Losartan (Cozaar), 156t
- diabetes, new-onset, 104t, 105
 - diuretic with, 112t, 158, 249, 251t
 - dosage, 156t, 157
 - in elderly patients, 161
 - ELITE 2 trial, 161
 - LIFE study of, 104t, 105, 161-162, 162t
 - RENAAL study of, 78-79, 158, 163-164, 165
 - side effects, 156t
- Losartan Intervention for End-point Reduction in Hypertension (LIFE) study, 161-162, 162t
- diabetes, new-onset, 104t, 105, 163
 - drugs compared, 161-162, 201
 - left ventricular hypertrophy, 161-162, 162t, 276
- Losartan with thiazide (Hyzaar), 112t, 158, 249, 251t
- Lotensin (benazepril), 119t
- Lotensin HCT, 112t, 250t
- Lotrel, 252t
- Low-density lipoprotein (LDL), 59
- Lozol (indapamide), 84t, 107, 114
- Lupus-like reaction/syndrome, 228t, 229
- LVH. See *Left ventricular hypertrophy (LVH)*.
- Macular rash, 145
- Magnesium intake/supplementation, 44, 49
- Malignant hypertension, 17
- MAPHY (Metoprolol Atherosclerosis Prevention in Hypertension) study, 98t, 198
- Masked hypertension, 26
- Mavik (trandolapril), 119t. See also *INVEST (International Verapamil SR/Trandolapril Study)*.
- Maxzide, 86, 242, 253t
- Medical Research Council studies. See *MRC (Medical Research Council) studies*.
- Metabolic syndrome, ACE inhibitors and, 147
- Methyldopa (Aldomet), 113t, 223-225, 224t, 237t, 238t, 252t. See also *Central agonists*.
- Methylodopa with thiazide (Aldoril), 113t, 252t
- Metolazone (Mikrox, Zaroxolyn), 84t, 115
- dosage, 84t
 - indications for, 241t
 - for vasodilator-induced fluid accumulation, 229
- Metoprolol Atherosclerosis Prevention in Hypertension (MAPHY) study, 98t, 198
- Metoprolol (Lopressor, Toprol-XL), 98t, 195, 196t-197t, 198, 200-201, 207, 213, 279
- Metoprolol with hydrochlorothiazide, 251t
- Metoprolol with thiazide (Lopressor HCT), 113t
- Micardis (telmisartan), 156t, 157
- Micardis HCT, 113t, 158, 251t
- Microalbuminuria, ARBs and, 163, 166-167, 168
- Microzide. See *Hydrochlorothiazide*.
- Midamor (amiloride), 85t
- MIDAS (Multicenter Isradipine Diuretic Atherosclerosis Study), 290t
- Migraine headache, drug indications for, 237t
- Minipress (prazosin), 215, 218t
- Minizide, 113t, 252t
- Minoxidil (Loniten), 227-229, 228t, 236t
- Mouretic, 86, 252t
- Moexipril (Univasc), 119t
- Moexipril with thiazide (Uniretic), 113t, 250t
- Monitoring of blood pressure, 26-28, 28t. See also *Blood pressure*.
- Monopril. See *Fosinopril*.
- Monopril HCT, 112t, 250t
- MRC (Medical Research Council) studies
- on β -blockers, 198, 199, 201
 - diuretics and glucose metabolism, 102t
 - diuretics and serum cholesterol, 98t-99t
 - on elderly, 92t, 282t, 291t
- MRFIT (Multiple Risk Factor Intervention Trial), 19, 20, 97, 98t, 102t, 115
- Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS), 290t
- Multiple Risk Factor Intervention Trial. See *MRFIT*.
- Myocardial infarction (MI)
- ACE inhibitors and, 72t, 120, 121-122, 123, 233, 244, 245
 - ACE inhibitors vs CCBs, 78, 128-130, 131t, 132, 152, 153t, 235
 - in ALLHAT, 135, 186
 - α -blockers and, 233
 - ARBs and, 169, 170t, 245, 246
 - aspirin and, 183
 - β -blockers and, 188, 198, 199-200, 200, 207, 241, 244, 283
 - CCBs and, 169, 170t, 184, 186, 233, 245, 292
 - increase possible with nifedipine, 183
 - dihydropyridines and, 169, 170t, 186
 - diuretics and, 233, 246
 - fatal, INSIGHT trial, 78
 - nonfatal, on ALLHAT, 135
 - SHEP study, 283
- Nadolol (Corgard), 196t-197t, 198
- Nadolol with bendroflumethiazide (Corzide), 113t, 206, 251t
- National Cholesterol Education Program, 59
- National Health and Nutritional Examination Studies (NHANES), 293, 295t
- National High Blood Pressure Program, 271
- Nebivolol (Bystolic), 209, 210t, 213-214
- advantages of, 214
 - in black patients, 210t, 212

cardiovascular mortality reduction with, 214
dosage, 210t, 214
in elderly patients, 214
as initial or add-on therapy, 245
nitric oxide and, 209, 214, 255
selectivity of, 212, 213
side effects, 209-211, 210t

Nephropathy. See also *Kidney disease; Renal entries*.
IDNT study of, 78-79, 164-166, 166, 291t

Neuropathy, diabetic, 149-151

NHANES (National Health and Nutritional Examination Studies), 293, 295t

Nicardipine SR (Cardene SR), 175t, 176

Nicotine, effect on catecholamines, 49

Nifedipine (Adalat CC, Procardia XL), 78, 104t, 175t, 176, 183-187, 290t

Nisoldipine (Sular), 152, 153t, 173, 175t
ABCD study, 152, 153t

Nitrendipine (Syst Eur trial), 71, 178-179, 282t, 284

Nitric oxide (NO)
ARBs and, 157
nebivolol and, 209, 214, 255

NOD (new-onset diabetes). See under *Diabetes*.

Nondihydropyridine CCBs, 173, 174t, 176. See also *Calcium channel blockers (CCBs)*.
action mechanisms of, 173, 174t
cardiovascular events and, 176, 185
combination therapy, 176
dosage, 174t
indications for, 176
INSIGHT trial, 78, 104t, 185, 186-187, 290t
long-acting formulas, 176, 184-185
NORDIL trial, 78, 185, 186, 279-280, 290t
physiologic effects, 174t
side effects, 174t, 176, 183
stroke and, 289

Nondippers, 27

Nordic Diltiazem (NORDIL) trial. See *NORDIL*.

NORDIL (Nordic Diltiazem) trial, 78, 104t, 185, 186, 279-280, 290t

Normodyne. See *Labetalol*.

Norvasc. See *Amlodipine*.

Obesity, 33-34, 29, 52, 53, 107, 272. See also *Weight loss*.

Office hypertension (white-coat hypertension), 25-26

Olmesartan (Benicar), 156t, 157

Olmesartan with amlodipine (Azor), 251t, 255

Olmesartan with thiazide (Benicar HCT), 113t, 158, 251t

Omega-3 fatty acids, 44-45

Osteoporosis, 42, 109, 240t

Pancreatitis, 91

Patient education on drug therapy, 66

Penbutolol (Levatol), 196t-197t

Perindopril (Aceon), 119t, 287

Perindopril Protection Against Recurrent Stroke Study (PROGRESS), 75, 114, 142-144, 143

Peripheral adrenergic inhibitors, 219-220, 221t. See also *specific drugs*.
drugs in this category, 221t
physiologic effects, 219, 221t
side effects, 219-220, 221t

Peripheral artery disease, β -blockers in, 240t

Peripheral vascular occlusive disease, 236t

Pharmacotherapy. See *Drug treatment of hypertension*.

Phenoxybenzamine (Dibenzylamine), 215

Phentolamine (Regitine), 215

Pheochromocytoma
 α -blockers for, 215
resistant hypertension and, 265t

Photosensitivity, 91

Pindolol (Visken), 195, 196t-197t

Plendil. See *Felodipine*.

Polythiazide (Renese), 84t

Polythiazide with prazosin (Minizide), 252t

Postural hypotension
 α -blockers and, 215, 216, 218t
 β -blockers with vasodilating properties and, 209
peripheral adrenergic inhibitors and, 221t

Potassium level, 91-95, 92t, 157

Potassium salt substitutes, 43-44

Potassium-sparing diuretics, 44, 83, 86, 93, 237t, 242. See also *specific drugs*.

Potassium supplementation, 42-44, 43t, 49, 237t

Prazosin (Minipress), 215-216, 218t. See also α_1 -*Blockers*.

Prazosin with polythiazide (Minizide), 113t, 252t

Pregnancy
chronic hypertension, indicated and contraindicated drugs, 238t
contraindicated drugs, 238t
ACE inhibitors, 146, 238t
ARBs, 157, 238t
RAAS inhibitors, 146
indicated drugs, 238t
preeclampsia, indicated and contraindicated drugs, 238t
toxemia of, methyldopa for, 226

Prehypertension, 22-25, 22t

Preterax, 151

PRIME (Program for Irbesartan Morbidity and Mortality Evaluation), 158

Prinivil. See *Lisinopril*.

Prinzide, 112t, 250t

Procardia XL. See *Nifedipine*.

Program for Irbesartan Morbidity and Mortality Evaluation (PRIME), 158

PROGRESS (Perindopril Protection Against Recurrent Stroke Study), 75, 114, 142-144, 143

Propranolol LA (Inderal LA), 196t-197t
InnoPran XL, 195
lipid solubility, 195
myocardial infarction and, 199-200

Propranolol with thiazide (Inderide), 113t

Propranolol (XR) with hydrochlorothiazide (Inderide LA), 251t

Prostaglandin levels, ACE inhibitors and, 117

Prostatic hypertrophy
 α -blockers in, 91, 217, 240t
diuretics and, 91

Proteinuria
ACE inhibitors and, 151
as indicator for treatment initiation, 53, 54

Pulmonary function, β -blockers and, 194

Pulse pressure, as risk criterion, 24-25

Quinapril (Accupril), 119t

Quinapril with thiazide (Accuretic), 113t, 250t

RAAS inhibitor. See *Renin-angiotensin-aldosterone (RAAS) inhibitor*.

RAAS. See *Renin-angiotensin-aldosterone system (RAAS)*.

Ramipril (Altace), 79, 119t
AASK study, 79, 153, 188-190
aliskiren with, 171
DREAM trial, 148
HOPE and HOPE-TOO studies, 121-122, 123

Rauwolfia alkaloids, 220, 221t

Rauwolfia serpentina, 221t

Rauzide, 220

Raynaud's phenomenon, β -blockers and, 194, 202t

Reduction in Endpoints in Noninsulin-dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan. See *RENAAL*.

Regitine (phentolamine), 215

Relaxation programs/biofeedback, 47-48, 48t, 49

RENAAL (Reduction in Endpoints in Noninsulin-dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan), 78-79, 158, 163-164, 165
 drugs compared, 163-164
 end-stage renal disease, 164, 165

Renal arterial disease
 drug contraindications in, 237t
 resistant hypertension and, 264t

Renal blood flow, β -blockers and, 205-206

Renal disease
 ACE inhibitors and, 79, 146-151, 233, 289
 ARBs and, 78-79
 β -blockers and, 205-206, 289
 CCBs and, 233, 289
 dihydropyridines and, 289, 290t-291t
 diuretics and, 109, 115, 232
 drug contraindications, 237t
 drug treatment and, 244
 end stage (ESRD), 164, 165
 ARBs and, 164-166, 165-166, 167
 progression to, drug treatment and, 280s
 progression of, drug treatment and, 280
 RAAS inhibitors and, 80
 resistant hypertension and, 261, 264t

Renal failure
 ACE inhibitors and, 149-150
 blood creatine levels in, 28, 146, 237t
 progression to, BP goals in diabetics and, 292-293
 sodium restriction in, 40

Renal function, ACE inhibitors and, 79, 146-151

Renal insufficiency
 drug contraindications in, 237t
 drug indications for, 241t
 prevention of, blood pressure lowering and, 292

Renese (polythiazide), 84t

Renin
 β -blockers and, 193
 high-renin hypertensives, 147

Renin inhibitors, 88, 171, 172t, 255
 action mechanism and sites, 118, 172t
 dosage, physiologic effects, and adverse reactions, 172t

Renin-angiotensin-aldosterone (RAAS) inhibitor, 80, 82. See also *ACE inhibitors*:
Angiotensin II receptor blockers.
 ARBs as, 159-160
 contraindications, 146
 CV morbidity/mortality reduction with, 71-73, 280
 diabetes and, 79, 80, 127, 144, 159-160
 diabetes, new-onset, reduction, 79
 indications for, 144
 as initial therapy, 149

Renin-angiotensin-aldosterone system (RAAS)
 β -blockers and, 193
 diuretics and, 88, 246
 renin inhibitors and, 171, 172t

Reserpine, 113t, 219-220, 221t, 227, 229, 237t, 253t

Reserpine with chlorthalidone (Diupres), 113t, 220, 252t

Reserpine with thiazide (Hydropres), 113t, 220, 253t

Resistant hypertension, 257-269

Risk stratification, treatment choices and, 55t

Rosiglitazone, 148

Salt reduction. See *Sodium restriction*.

Salt substitutes, 43-44

SBP. See *Systolic blood pressure (SBP)*.

SCOPE (Study on Cognition and Prognosis in the Elderly), 104t, 168-169, 179, 284

Sectral. See *Acebutolol*.

Severe hypertension, 24

Sexual dysfunction, 90-91, 203t

SHEP (Systolic Hypertension in the Elderly Program), 281, 282t, 283
 blood pressure in, 26-27, 296
 cardiovascular events and mortality, 67-68, 95, 96, 179, 281, 282t, 283
 diabetes, 100, 105t, 148, 149, 281
 diuretics in, 96, 99t, 100, 102t, a
 drugs compared, 281
 J-shaped curve/DBP in, 67-68
 outcomes, 281, 282t, 283
 potassium level on, 95

Sick sinus syndrome, 202t, 236t

Skin rash, 91

Sleep apnea, resistant hypertension and, 265t

Smoking, cessation of, 34t, 49

Sodium restriction, 34t, 39-41, 43-44, 48

Spironolactone (Aldactone), 85t, 93-95, 254

Spironolactone with hydrochlorothiazide (Aldactazide), 253t

Statins, in diabetics, 59

Stepped-care, 231-232

STOP-Hypertension-2 (Swedish Trial in Older Patients with Hypertension), 71-73, 76, 78, 127-130, 279-280
 β -blockers on, 199
 drugs compared, 127
 frequency of CV events, 131t, 235
 mortality and morbidity outcomes, 129, 132, 284, 290t
 new-onset diabetes, 104t

Stroke. See also *Transient ischemic attacks*.
 ACE inhibitor and diuretic as protective, 75, 114
 ACE inhibitors, 124-125, 126, 128-130, 128t, 131t, 132, 137, 232
 ARBs and, 79, 246
 ARBs vs β -blockers, 79
 β -blockers and, 128t, 129, 131t, 132, 233
 CCBs and, 73, 79, 131t, 132, 137, 178, 245
 decline in, 271, 272, 272
 diuretics and, 142-144, 143, 232
 drug treatment results, 271, 272, 272, 282t, 283, 284
 in elderly patients, 282t, 283, 284
 indapamide and, 114
 long-term antihypertensive drug treatment and, 59-60, 61
 prevention, drugs indicated for, 72t

Studies. See *Trials and studies*.

Study on Cognition and Prognosis in the Elderly (SCOPE), 168-169, 179, 284

Sular. See *Nisoldipine*.

Swedish Trial in Older Patients with Hypertension. See *STOP-Hypertension-2*.

Sympathectomy, 17

Sympathomimetic action, β -Blockers with, 195, 196t-197t

Syst Eur (Systolic Hypertension in Europe Multicentre Trial), 71, 178-179, 282t, 284

Systolic blood pressure (SBP), 19-21, 20
 classification of hypertension and, 19-21
 CV risk and, 19-21, 20, 25
 in diagnosis, 19-21, 20, 31
 goal, elderly patients, 285, 286
 reduction with lifestyle modifications, 38t
 thresholds for hypertension definition/treatment, 28t, 51-52

Systolic hypertension, elderly people, percentage not treated, 21, 21. See also *Isolated systolic hypertension (ISH)*.

Systolic Hypertension in Europe (Syst Eur) Multicentre Trial, 71, 178-179, 282t, 284

Systolic Hypertension in the Elderly Program. See *SHEP*.

Tachycardia
 α -blockers and, 215
 β -blockers and, 194, 198
 dihydropyridine CCBs and, 176, 183
 vasodilators and, 227, 228t

Tarka, 252t

Taste and appetite loss, ACE inhibitors, 117, 145

Tekturna (aliskiren), 63, 88, 171, 172t

Telmisartan (Micardis), 156t, 157

Telmisartan with thiazide (Micardis HCT), 113t, 158, 251t

Tenex (guanfacine), 223, 224t

Tenoretic, 112t, 206, 251t

Tenormin. See *Atenolol*.

Terazosin (Hytrin), 215, 218t. See also α_1 -Blockers.

- action mechanism, 216
- dosage, 216-217, 218t
- physiologic effects, 218t
- for prostatic hypertrophy, 91
- side effects, 215-216

Teveten (eprosartan), 156t

Teveten HCT, 112t, 158, 250t

Thiazides, 83, 84t, 139-140. See also *Diuretics; specific drugs*.

- action mechanism, 83
- action sites, 86
- ALLHAT trial. See *ALLHAT*.
- ANBP 2 study, 140-142, 141
- dosage, 84t
- drug combinations with, 86, 95, 109, 177, 212
- combination medications, 112t-113t, 242, 250t-253t
- drugs in this category, 84t
- duration of action, 83, 84t
- effectiveness of, 83, 241t
- hyperglycemia risk, 107
- indications and contraindications for, 241t
- as initial therapy, 68-69, 139-140, 238, 240t, 241t, 242
- loop diuretics vs, 241t
- potassium supplementation with, 44
- side effects. See *Diuretics, side effects*.
- in treatment algorithm, 74

Tiazac, 173, 174t. See also *Diltiazem*.

Timolide, 113t, 251t

Timolol, myocardial infarction and, 199-200

Timolol with thiazide (Timolide), 113t, 251t

TOMHS (Treatment of Mild Hypertension Study), 51, 64t, 81, 90-91, 99t, 103t, 204

TONE (Trial of Nonpharmacologic Interventions in the Elderly), 39-40

Toprol-XL. See *Metoprolol*.

Torseamide (Demadex), 85t, 114-115, 229, 241t

Trandate. See *Labetalol*.

Trandolapril (Mavik), 119t

- diabetes, new-onset and, 104t, 186
- INVEST study, 104t, 185-186, 290t

Trandolapril/verapamil XR (Tarka), 252t

Transient ischemic attacks, 75, 114, 283. See also *Stroke*.

Treatment of Mild Hypertension Study. See *TOMHS*.

Trial of Nonpharmacologic Interventions in the Elderly (TONE), 39-40

Trial of Preventing Hypertension (TROPHY), 23

Trials and studies, 272-279, 275t, 277t-278t. See also *specific trials and studies*.

- AASK, 79, 153, 188-190, 200-201
- ABCD, 78, 152-153, 153t, 290t
- ADVANCE, 151
- ALLHAT, 130-140. See also *ALLHAT (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial)*.
- ANBP 2, 140-142, 141. See also *ANBP 2 (Australian National Blood Pressure) study*.
- ASCOT, 187-188, 189. See also *ASCOT (Anglo-Scandinavia Cardiac Outcomes Trial)*.
- Blood Pressure Lowering Treatment Trialists Collaboration, 73, 127-128
- CALM, 163
- CAPP, 122-126. See also *Captopril Prevention Project*.
- CHARM, 104t, 161
- CONVINCE, 60, 133
- DASH, 36, 38t, 40, 45
- DREAM, 148
- ELITE 2, 161
- EWPHE, 98t, 102t, 282t
- FACET, 78, 151-152, 290t
- GEMINI, 213
- HAPPHY, 98t, 102t, 198
- HDFP, 27, 66, 100, 100. See also *HDFP (Hypertension Detection and Follow-up Program)*.
- HOPE, 121-122. See also *HOPE (Heart Outcomes Prevention Evaluation)*.
- HOPE-TOO, 122, 123
- HOT, 180-183, 181t-182t. See also *HOT (Hypertension Optimal Treatment) trial*.
- HYVET, 114, 287-288, 287t
- IDNT, 78-79, 164-166, 166, 291t
- INSIGHT, 78, 104t, 185, 186-187, 290t
- INVEST, 104t, 185-186, 248, 290t
- IRMA 2, 78-79, 166-167, 168
- LIFE, 104t, 105, 161-162, 162t, 163, 201
- MAPHY, 98t, 198
- MIDAS, 290t
- MRC, 98t-99t, 102t, 198, 199, 201, 282t, 291t. See also *MRC (Medical Research Council) studies*.
- MRFIT, 19, 20, 97, 98t, 102t, 115
- NHANES, 293, 295t
- NORDIL, 78, 185, 186, 279-280, 290t
- Oslo, 98t, 102t
- PRIME, 158
- PROGRESS, 75, 114, 142-144, 143
- RENAAL, 78-79, 158, 163-164, 165
- SCOPE, 104t, 163, 168-169, 179
- SHEP, 281, 282t, 283. See also *SHEP (Systolic Hypertension in the Elderly Program)*.
- STOP-Hypertension-2, 127-130, 131t. See also *STOP-Hypertension-2 (Swedish Trial in Older Patients with Hypertension)*.
- Syst Eur, 71, 178-179, 282t, 284
- TOMHS, 51, 64t, 81, 90-91, 99t, 103t, 204
- TONE, 39-40
- TROPHY, 23
- UKPDS, 126-127, 128t. See also *UKPDS (United Kingdom Prospective Diabetes Study)*.
- VA, 80-81, 99t, 103t
- Val-HeFT, 161
- VALUE, 169, 170t. See also *VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial*.
- VHAS, 96, 184-185, 290t
- Triamterene (Dyrenium), 85t
- Triamterene with hydrochlorothiazide (Dyazide, Maxzide), 253t
- TROPHY (Trial of Preventing Hypertension), 23

UKPDS (United Kingdom Prospective Diabetes Study), 71, 76, 101, 126-127, 128t, 180-182, 200, 207, 280, 290t

Uniretic, 113t, 250t

United Kingdom Prospective Diabetes Study. See *UKPDS*.

Univasc (moexipril), 119t

Uric acid, diuretics and, 92t, 108

VA (Veterans Administration) studies, 80-81, 99t, 103t

Val-HeFT (Valsartan Heart Failure Trial), 161

Valsartan (Diovan), 156t. See also *VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial*.

- aliskiren with, 171
- diabetes, new-onset, 104t-105t, 105
- diuretic with, 113t, 159, 251t
- dosage, 156t, 157
- physiologic effects, 156t
- side effects, 156t

Valsartan Heart Failure Trial (Val-HeFT), 161

Valsartan with amlodipine (Exforge), 251t

Valsartan with thiazide (Diovan HCT), 113t, 159, 251t
VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, 76, 100, 104t-105t, 105, 148, 149, 163, 169, 170t, 177, 188, 190, 280
Vascular resistance studies, 30-31, 32
Vaseretic, 112t, 250t
Vasodilators, 117, 227-230, 228t. See also *ACE inhibitors*.
 action mechanism, 118
 contraindications, 227, 236t
 diuretics with, 229
 drugs in this category, 228t
 effectiveness of, 227
 fluid accumulation with, 227, 228t, 229
 indications for, 229
 initial monotherapy, recommended against, 229
 physiologic effects, 227, 228t, 243t
 side effects, 227, 228t
Vasotec. See *Enalapril*.
Ventricular ectopy, 94t
Verapamil (Calan, Covera, Isoptin, Verelan), 174t
 action mechanisms, 173, 174t, 176
 atherosclerosis and (VHAS study), 96, 184-185, 290t
 AV/SA conduction block and, 176
 coronary heart disease and, 176
 dosage, 174t
 formulations, 174t, 252t
 indications and contraindications for, 176, 236t
 lipid levels and, 96
 side effects, 174t, 184
 with trandolapril (INVEST study), 104t, 185-186, 290t
Verapamil in Hypertension Atherosclerosis Study (VHAS), 96, 184-185, 290t
Verelan. See *Verapamil*.
Veterans Administration (VA) studies, 80-81, 99t, 103t
VHAS (Verapamil in Hypertension Atherosclerosis Study), 96, 184-185, 290t
Visken (pindolol), 195, 196t-197t

Weight loss, 33-39, 34t, 48
White-coat hypertension (office hypertension), 25-26
WHO-ISH (World Health Organization-International Society of Hypertension), on lowering BP vs specific drug therapy, 75, 82
Wine, recommended intake limit, 45, 49
World Health Organization-International Society of Hypertension (WHO-ISH), 75, 82

Yoga, 47

Zaroxolyn, 84t, 115
 for vasodilator-induced fluid accumulation, 229
Zebeta. See *Bisoprolol*.
Zestoretic, 112t, 250t
Zestril. See *Lisinopril*.
Ziac, 112t, 251t